Log In
BCIQ
Print this Print this
 

TBI-9341m

  Manage Alerts
Collapse Summary General Information
Company TheraBiol Inc.
DescriptionUndisclosed immunogen that enables the development of mAbs that neutralize the infectivity of both HIV-R5 and HIV-X4 subtypes
Molecular Target
Mechanism of ActionImmunotherapy
Therapeutic ModalityActive immunotherapy
Latest Stage of DevelopmentDiscovery
Standard IndicationHIV / AIDS
Indication DetailsTreat HIV/AIDS
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today